Loading...
NPI 1083134209 · The Woodlands, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Wise Diagnostic Systems, LLC is a clinical medical laboratory provider located in The Woodlands, Texas. This profile covers 21 Medicare and 38 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Wise Diagnostic Systems, LLC |
| Address | 1776 Woodstead Ct Ste 107 |
| City | The Woodlands |
| State | TX |
| ZIP | 77380 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | June 20, 2017 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2M |
| Medicaid | $451.8K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
21 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 20,650 | $30 | $702.1K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 5,400 | $70 | $372.7K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 2,600 | $70 | $192K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 4,980 | $30 | $169.3K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 4,340 | $30 | $147.6K |
| 81226 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily D, polypeptide 6, also known as CYP2D6. | 200 | $440 | $85.6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 2,290 | $30 | $57.3K |
| 81225 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 19, also known as CYP2C19. | 150 | $290 | $41.5K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 1,070 | $30 | $36.4K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 1,070 | $30 | $36.4K |
Showing 1–10 of 21
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
21 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87150 | 9 | 30 | 1,260 | $30 | $430.3K |
| 87798 | 21 | 300 | 790 | $30 | $265.1K |
| 87801 | 5 | 120 | 170 | $70 | $86.5K |
| 87481 | 24 | 270 | 150 | $30 | $68.8K |
| 87498 | 20 | 30 | 120 | $30 | $45.9K |
| U0004 | 2 | 20 | 50 | $70 | $40.4K |
| 87486 | 36 | 60 | 90 | $30 | $32.7K |
| 87581 | 37 | 70 | 80 | $30 | $32.2K |
| 81226 | 2 | 30 | 40 | $430 | $31.3K |
| 87640 | 30 | 250 | 70 | $30 | $25.9K |
Showing 1–10 of 21
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
38 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 29,390 | $10 | $235.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 23,040 | $1 | $69.1K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 4,840 | $10 | $67.8K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 3,710 | $10 | $22.2K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 4,370 | $10 | $21.9K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 2,770 | $1 | $8.3K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 2,230 | $1 | $4.5K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 1,400 | $1 | $4.2K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 490 | $10 | $3.9K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 3,720 | $1 | $3.7K |
Showing 1–10 of 38
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
38 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81408 | The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 9 molecular pathology code. | 8 | 40 | 100 | $230 | $335.3K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 4 | 100 | 470 | $50 | $319.1K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 37 | 240 | 420 | $30 | $296.8K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 197 | 290 | 410 | $20 | $225K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 203 | 300 | 410 | $20 | $223.4K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 103 | 150 | 320 | $20 | $184K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 17 | 110 | 360 | $40 | $174.9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 14 | 260 | 640 | $20 | $137.2K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 342 | 350 | 230 | $70 | $120.3K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 32 | 170 | 440 | $20 | $93.6K |
Showing 1–10 of 38
Other providers in the same ZIP code as Wise Diagnostic Systems, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Pediatric Urgent Care PA | TX | Urgent Care Clinic/Center | $0 | $25.2M |
| Maxim Healthcare Services, Inc. | TX | Home Health Agency | $0 | $19M |
| Shaun S. Varghese, M.d., PLLC | TX | Neurology with Special Qualifications in Child Neurology Physician | $0 | $16.8M |
| Singleton Associates PA | TX | Diagnostic Radiology Physician | $0 | $16.2M |
| Guy Burrows | TX | Neurology Physician | $11.3M | $0 |
| Trifecta Pharmacy LLC | TX | Community/Retail Pharmacy | $7.9M | $1.3K |
| Samir Shirodkar | TX | Urology Physician | $3.4M | $0 |
| Randall Johnson | TX | Rheumatology Physician | $2.5M | $0 |
| Asit Choksi | TX | Medical Oncology Physician | $2.4M | $0 |
| Carolyn Chen | TX | Ophthalmology Physician | $2M | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.